Do you want to read an article? Please log in or register.
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
Related content
RECOMMENDED
Multiple Sclerosis
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
doi: 10.1016/S1474-4422(20)30070-3.
RECOMMENDED
Multiple Sclerosis
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders
Lancet Neurol.
Ciccarelli O, Cohen JA, Reingold SC, Weinshenker BG; International Conference on Spinal Cord Involvement and Imaging in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
doi: 10.1016/S1474-
RECOMMENDED
Multiple Sclerosis
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
J Neurol.
Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A
doi: 10.1007/s00415-018-9092-4.
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Brain and cord imaging features in neuromyelitis optica spectrum disorders
Ann Neurol.
Cacciaguerra L, Meani A, Mesaros S, Radaelli M, Palace J, Dujmovic-Basuroski I, Pagani E, Martinelli V, Matthews L, Drulovic J, Leite MI, Comi G, Filippi M, Rocca MA
doi: 10.1002/ana.25411.
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
doi: 10.1016/S1474-4422(20)30078-8.
RECOMMENDED
Multiple Sclerosis
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
N Engl J Med.
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J
doi: 10.1056/NEJMoa1901747.
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
N Engl J Med.
Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM
doi: 10.1056/NEJMoa1900866.
Psychosis and Schizophrenia
Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis
Neurosci Biobehav Rev.
Okhuijsen-Pfeifer C, Sterk AY, Horn IM, Terstappen J, Kahn RS, Luykx JJ
doi: 10.1016/j.neubiorev.2020.01.017.
RECOMMENDED
Further Publications NeurologyFurther Publications Psychiatry
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 1
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H
doi: 10.1016/S1474-4422(20)30066-1.